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Bronchodilator treatment in asthma
EDrTOR,-Win Castle and colleagues have now provided data that were missing from their report on the safety of salmeterol in the large British postmarketing surveillance study'-namely, the ages of patients at death.2 They suggest that, given the range of ages, the only appropriate statistic to use is overall mortality.2 Failure to analyse by age, however, obscures the important observation that the proportion of younger people among those dying of asthma during salmeterol treatment seems to have increased.
We have compared the data reported from the salmeterol study' 2 with mortality data for England and Wales for 1988 , 1989 , and 1990 provided by the Office of Population Censuses and Surveys;
we have assumed that the age distribution of the study population was similar to that of the wider asthmatic population. Half of the patients treated with salmeterol who died were aged under 50 compared with only 18% of patients in national statistics, and three quarters were under 65 compared with only 39% in national statistics. The figure shows the observed cumulating proportion of deaths by five year age group among those who died while being treated with salmeterol2 compared with the expected cumulating proportion of deaths by age calculated from national statistics. Observed cumulating proportion of deaths from asthma by five year age group in subjects dying of asthma during salmeterol treatment' 2 compared with expected cumulating proportion denived from national statistics for England and Wales 1988-90 Comparative risks of death should be calculated from the prevalence of asthma in each age group (which is not known) and the number of subjects in each age group exposed to salmeterol in the surveillance study (which Castle and colleagues presumably do know). In the absence of these data, the calculations above provide the only means of relating actual mortality to expected mortality; they leave us with the concern that salmeterol seems to increase the risk of death among younger people. We remain surprised that five of the 14 deaths from asthma reported by Castle and colleagues occurred in hospital. The statement that these patients "were not found to have had unusual features" is singularly uninformative. Death from asthma should be exceedingly rare once a patient is in hospital; again we question whether these subjects had attacks resistant to usual treatment. How many of these subjects were using salmeterol? High dose inotropic support in septic shock EDITOR,-We endorse most of J D Edwards's recommendations on the management of septic shock.' We cannot, however, agree with the statement that treatment directed at attaining high levels of oxygen delivery and oxygen consumption has been well validated. Two of the studies quoted to support this contention were not controlled,2' and the third showed an improvement in survival only when the groups were redefined so that one consisted of control and protocol patients who achieved a high cardiac index (> 4 5 I/min/m2) while the other comprised all those who failed to achieve this value.4 Although high levels of oxygen delivery and oxygen consumption are clearly associated with survival from critical illness, there are no convincing data to suggest that the aggressive use of inotropic support in an attempt to achieve values of these variables seen in survivors improves outcome in septic shock. Rather-provided volume replacement is adequate, blood pressure is maintained, and inotropes are used appropriately to achieve a normal cardiac output-the observed relation may simply reflect the physiological reserve and the severity of the insult. Indeed, the use of high dose inotropic support may be associated with worsening of the maldistribution of flow, cardiac arrhythmias, and myocardial ischaemia.5 Until the results of prospective randomised controlled trials analysed according to intention to treat are published the value of high dose inotropic support remains uncertain. Contraceptives and the selected drugs list EDIORR,-Contraceptives are among the 10 categories of drugs to be added to the selected drugs list. Both the editorial and the correspondence on the selected list failed to emphasise the consequences of a reduction in choice for women needing contraception.' 2 Many people argue that a reduction in the range of contraceptives would lead to more women stopping taking them and more unwanted pregnancies. The most widely used reversible method of contraception in Britain, and the one with the most scope for a reduction in prescribing costs, is the combined contraceptive pill, with prices ranging from 60p to £2.40 for a 21 day course. While one particular brand may be suitable for many users, some women need an alternative preparation to obtain safe contraception that is free of side effects. We have investigated the prevalence of changes in the brand prescribed in our family planning and well woman centre in Edinburgh. The records of the first 2000 new patients to register in 1988 were analysed to determine the number of changes of brand of combined pill that occurred over the subsequent five years and the reasons for the change. A total of 1536 women attended for advice on contraception, 73% of whom used the pill at some time during the five years. Altogether 699 women used only one brand of pill and 417 changed their brand at least once (105 women switched brands twice and 60 switched brands three times or more). Where a reason for change was recorded (n = 670) breakthrough bleeding was the commonest (132 women). Some 40 changed brands on the advice of the doctor. Forty one women were known to have had a termination of pregnancy during the period of the study: 35 of these terminations occurred in the women who changed their pill at least once.
Clearly, an appreciable proportion of women will try a different pill in an attempt to overcome troublesome side effects. Women who have difficulty in finding an acceptable method seem to be at greater risk of an unwanted pregnancy. A reduction in the choice of available pills would reduce the chance of some women finding an acceptable one. Sixteen of the brands of combined pill currently available cost under £1 for 21 days; retaining these would result in a fairly large selected list. We believe not only that there must be choice but that the choice must include the modern, third generation pills containing progestogen, which may be safer and more effective. Cimetidine and weight loss ED1TOR,-P Mangtani and P Seed raise three questions' about our study of cimetidine and weight loss.2 They suggest that inclusion of the non-compliant patients would have resulted in a significant difference in weight loss between the placebo and cimetidine groups. Analysis of our trial by intention to treat did not, however, change the outcome or the conclusions. Furthermore, the small number of non-compliant patients and the about average weight loss of these patients could not explain the average increase in weight during the third week ofthe study as suggested.'
Mangtani and Seed also suggest that the 446 BMJ VOLUME 307 14 AUGUST 1993
